“DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of innovative healthcare research, services and solutions to federal agencies, today announced that it has recently been awarded multiple task orders and contracts related to COVID-19 testing and analysis that are expected to add at least $15 million of incremental revenue, with the majority anticipated in calendar 2020. The task orders encompass the evaluation of various treatment alternatives and the impact of COVID-19 on other chronic conditions, as well as the development of health communication tools to exchange emerging data among numerous scientific stakeholders. These efforts are being performed for the U.S. Department of Health and Human Services.”
“’DLH has supported the National Institutes of Health and the Centers for Disease Control and Prevention for decades in the fight against infectious diseases, and we are proud to continue in the current effort addressing COVID-19,’ said DLH President and Chief Executive Officer Zach Parker…” Read the full article here.
Source: DLH Conducting Trials and Leading Studies Related to COVID-19 – July 21, 2020. DLH.
